Zenas BioPharma, Inc. has 16 Schedule 13D or 13G filings on record since 2025-08-06. 5 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 14.3% | 7,652,255 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 |
| InnoCare Pharma Inc. | 10.4% | 7,000,000 | SCHEDULE 13G/A, 2026-09-08 | 2026-08-26 |
| Wellington Management Group LLP | 10.1% | 6,566,134 | SCHEDULE 13G, 2026-09-08 | 2026-08-31 |
| SR One Capital Management, LLC | 7.7% | 5,037,854 | SCHEDULE 13D/A, 2026-08-17 | 2026-08-13 |
| Moulder Leon O Jr | 5.09% | 3,220,880 | SCHEDULE 13D, 2026-05-05 | 2026-04-29 |
| Longitude Capital Partners IV, LLC | 4.9% | 1,832,669 | SCHEDULE 13D/A, 2025-10-14 | 2025-10-09 |
| Enavate Sciences GP, LLC | 4.9% | 3,245,404 | SCHEDULE 13D/A, 2026-08-19 | 2026-08-19 |
| Novo Holdings A/S | 4.7% | 2,000,000 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Purpose of Transaction (Item 4)
Moulder Leon O Jr
The information set forth in Item 3 of this Statement is incorporated herein by reference. Mr. Moulder serves as the Chairman of the Issuer's Board of Directors and as its Chief Executive Officer. In such capacity, Mr. Moulder has influence over the corporate activities of the Issuer, including activities that may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Except as described herein, the Reporting Persons have no present plans or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. However, the Reporting Persons reserve the right to formulate in the future plans or proposals which may relate to or result in the transactions described in subparagraphs (a) through (j) of this Item 4. In addition to the foregoing, the Reporting Persons may engage in discussions from time to time with other members of the Issuer's management and/or Board of Directors and/or with other stockholders of the Issuer and/or other third parties. Such discussions may include, without limitation, discussions with respect to the governance, board composition, management, operations, business, assets, capitalization, financial condition, strategic plans and future of the Issuer, as well as other matters related to the Issuer. These discussions may also include a review of options for enhancing stockholder value through, among other things, various strategic alternatives …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-05; the filing has the rest
Longitude Capital Partners IV, LLC
The information set forth in Item 4 of the Original Schedule 13D is incorporated herein by reference.Item 4 of the SCHEDULE 13D/A filed 2025-10-14
SR One Capital Management, LLC
Not applicable.Item 4 of the SCHEDULE 13D/A filed 2026-08-17
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-06 | Fmr LLC | 7.9% | SCHEDULE 13G/A |
| 2025-09-08 | Fmr LLC | 11% | SCHEDULE 13G/A |
| 2025-10-09 | Leon O. Moulder, Jr. | 4.8% | SCHEDULE 13D/A |
| 2025-10-14 | Longitude Capital Partners IV, LLC | 4.9% | SCHEDULE 13D/A |
| 2025-10-14 | SR One Capital Management, LLC | 9.4% | SCHEDULE 13D/A |
| 2025-10-14 | Enavate Sciences GP, LLC | 7.3% | SCHEDULE 13D/A |
| 2025-10-15 | InnoCare Pharma Inc. | 9.4% | SCHEDULE 13G |
| 2025-11-14 | Novo Holdings A/S | 4.7% | SCHEDULE 13G/A |
| 2026-01-14 | Leon O. Moulder, Jr. | 5.16% | SCHEDULE 13D |
| 2026-02-05 | Fmr LLC | 14.3% | SCHEDULE 13G/A |
| 2026-04-02 | Leon O. Moulder, Jr. | 4.79% | SCHEDULE 13D/A |
| 2026-05-05 | Moulder Leon O Jr | 5.09% | SCHEDULE 13D |
| 2026-08-17 | SR One Capital Management, LLC | 7.7% | SCHEDULE 13D/A |
| 2026-08-19 | Enavate Sciences GP, LLC | 4.9% | SCHEDULE 13D/A |
| 2026-09-08 | Wellington Management Group LLP | 10.1% | SCHEDULE 13G |
| 2026-09-08 | InnoCare Pharma Inc. | 10.4% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Zenas BioPharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.